Rhabdomyosarcoma
The commonest soft-tissue sarcoma of childhood; PAX3::FOXO1 fusion-positive and metastatic disease do worst.
Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.
- Readout dueReadout due: NCT07686198 reached primary completion
Goldman, Butterwick, Fitzpatrick and Groff. Study Comparing Two Serums With Intense Pulsed Light for the Treatment of Moderate to Severe Photodamage and Crepiness on the Forearms
- PaperA phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M).
Pratilas CA, Yohe ME, Williams PM et al. The oncologist.
- New trialNew Ph1 trial: NCT07888114
Beijing Tongren Hospital. Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities
- Readout dueReadout due: NCT06521567 reached primary completion
GlaxoSmithKline. A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
- Readout dueReadout due: NCT04388839 reached primary completion
H. Lee Moffitt Cancer Center and Research Institute. Evolutionary Therapy for Rhabdomyosarcoma
A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.